Wedbush Has Positive Estimate for Vor Biopharma Q3 Earnings

Key Points

• Wedbush analysts have raised their Q3 2025 earnings estimates for Vor Biopharma from ($0.19) to ($0.03) per share, maintaining an "Outperform" rating on the stock.
• The consensus rating for Vor Biopharma is currently "Moderate Buy" with an average price target of $6.07, despite several analysts downgrading their ratings recently.
• Vor Biopharma's stock is trading at $1.98, showing a significant increase from its 12-month low of $0.13, with a market capitalization of approximately $250.75 million.

Vor Biopharma Inc. (NYSE:VOR - Free Report) - Equities research analysts at Wedbush increased their Q3 2025 EPS estimates for shares of Vor Biopharma in a research report issued to clients and investors on Wednesday, August 13th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of ($0.03) per share for the quarter, up from their previous estimate of ($0.19). Wedbush has a "Outperform" rating on the stock. The consensus estimate for Vor Biopharma's current full-year earnings is ($1.42) per share. Wedbush also issued estimates for Vor Biopharma's Q4 2025 earnings at ($0.03) EPS, Q1 2026 earnings at ($0.03) EPS, Q2 2026 earnings at ($0.03) EPS, Q3 2026 earnings at ($0.03) EPS, Q4 2026 earnings at ($0.03) EPS and FY2026 earnings at ($0.14) EPS.

VOR has been the subject of several other research reports. Jones Trading downgraded shares of Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 8th. JMP Securities reissued a "market perform" rating and issued a $6.00 target price on shares of Vor Biopharma in a research note on Friday, May 9th. HC Wainwright restated a "buy" rating and issued a $3.00 price target on shares of Vor Biopharma in a report on Thursday, August 14th. Citizens Jmp cut Vor Biopharma from a "strong-buy" rating to a "hold" rating in a report on Friday, May 9th. Finally, Baird R W cut Vor Biopharma from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 8th. Five equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $6.07.

Vor Biopharma Stock Performance

VOR stock traded up $0.01 during trading on Friday, hitting $2.05. The stock had a trading volume of 1,890,911 shares, compared to its average volume of 7,965,143. The company's 50 day moving average price is $1.62 and its two-hundred day moving average price is $1.04. Vor Biopharma has a 1-year low of $0.13 and a 1-year high of $3.29. The stock has a market cap of $259.70 million, a price-to-earnings ratio of -1.24 and a beta of 2.06.

Institutional Trading of Vor Biopharma

Several large investors have recently added to or reduced their stakes in VOR. Money Concepts Capital Corp increased its holdings in Vor Biopharma by 106.1% in the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock valued at $37,000 after purchasing an additional 26,535 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock worth $61,000 after acquiring an additional 58,247 shares in the last quarter. XTX Topco Ltd acquired a new position in Vor Biopharma during the 2nd quarter worth approximately $66,000. OMERS ADMINISTRATION Corp acquired a new position in Vor Biopharma during the 1st quarter worth approximately $100,000. Finally, Trustees of Columbia University in the City of New York acquired a new position in Vor Biopharma during the 4th quarter worth approximately $102,000. 97.29% of the stock is currently owned by institutional investors and hedge funds.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.